Montefiori, D. C., Huang, Y., Karuna, S., Allen, M., Kochar, N., Chappuis, S., … Pantaleo, G. (2012). rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1. In Retrovirology (Vol. 9). Springer Science and Business Media LLC. https://doi.org/10.1186/1742-4690-9-s2-p132

Montefiori, D. C., Y. Huang, S. Karuna, M. Allen, N. Kochar, S. Chappuis, J. Gaillard, et al. “rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1.” In Retrovirology, Vol. 9. Springer Science and Business Media LLC, 2012. https://doi.org/10.1186/1742-4690-9-s2-p132.

Montefiori DC, Huang Y, Karuna S, Allen M, Kochar N, Chappuis S, et al. rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1. In: Retrovirology. Springer Science and Business Media LLC; 2012.

Montefiori, D. C., et al. “rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1.” Retrovirology, vol. 9, no. S2, Springer Science and Business Media LLC, 2012. Crossref, doi:10.1186/1742-4690-9-s2-p132.

Montefiori DC, Huang Y, Karuna S, Allen M, Kochar N, Chappuis S, Gaillard J, Tomaras G, Graham B, Bart P, Pantaleo G. rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1. Retrovirology. Springer Science and Business Media LLC; 2012.